We were recently awarded Phase I funding for the CRACK IT challenge to create a human in vitro T-cell dependent antibody response assay (TDAR) using OoC technology. Our TDAR assay could enable the assessment of preclinical immunomodulatory therapeutics and reduce testing in non-human primates. This will contribute towards 3Rs advances in preclinical sciences and safety assessment across the bioscience sector.
Click here for more information about the press release and here for the current status of the challenge.
Sponsors: Bayer AG, GSK, Merck Healthcare KGaA and Novartis Pharma AG.
